Synagis 50mg Injection contains the active substance Palivizumab, a monoclonal antibody used primarily to prevent severe respiratory syncytial virus (RSV)-related lower respiratory tract infections in high-risk children. 

Synagis 50mg Injection is prescribed to infants and young children at high risk for severe RSV infection, including those born prematurely (≤35 weeks gestational age), those with bronchopulmonary dysplasia (BPD), and children with hemodynamically significant congenital heart disease (CHD). It works by inhibiting the RSV F protein, preventing the virus from entering and infecting healthy cells. 

Before starting treatment with Synagis 50mg Injection, inform your doctor if your child has any history of allergies or bleeding disorders, as well as any other medications they are currently taking. While Synagis 50mg Injection is generally well-tolerated, regular monitoring is recommended, particularly for any signs of hypersensitivity reactions or coagulation disorders.

Synagis 50mg Injection is a monoclonal antibody developed to prevent severe RSV-related lower respiratory tract disease in high-risk children. It works by inhibiting the RSV F protein, blocking the virus from entering cells, and has proven to be safe and effective in specific high-risk patient populations.

Synagis 50mg Injection is used to prevent RSV infection in children at high risk, including:

Children with bronchopulmonary dysplasia (BPD).

Infants born prematurely (≤35 weeks gestational age).

Children with hemodynamically significant congenital heart disease (CHD).

Synagis 50mg Injection is a recombinant humanized monoclonal antibody that provides passive immunity against RSV by binding to the RSV F protein on the virus surface. This action blocks a critical step in the fusion process and prevents RSV-infected cells from fusing with neighboring cells, thus inhibiting the spread of the virus.

Synagis 50mg Injection should be administered intramuscularly at a dose of 15 mg per kg, preferably in the anterolateral thigh. Inspect the vial for any particulate matter or discoloration before use and discard if found. Withdraw the dose using a sterile technique and administer it immediately. For doses over 1 mL, divide the dose. Do not re-enter the vial or reuse syringes and needles. Ensure a healthcare professional administers the drug for proper technique and safety.

Fever

Rash

Injection site reactions (e.g., pain, swelling)

Mild hypersensitivity reactions (e.g., urticaria, pruritus)

Anaphylaxis (severe allergic reactions, including shock)

Respiratory issues (e.g., dyspnea, respiratory failure, cyanosis)

Hypotension (low blood pressure)

Severe thrombocytopenia (low platelet count)

Coagulation disorders (increased bleeding risk)

Severe hypersensitivity reactions (e.g., angioedema, unresponsiveness)

provider about any other medications or supplements your child is taking, as some may interact with Synagis 50mg Injection. Always follow your doctor’s instructions and seek advice before starting or stopping any other treatments.

Store between 2°C and 8°C (36°F and 46°F) in its original container. Do not freeze. Use before expiration.

Administered by healthcare professionals as an intramuscular injection. Use with caution in children with thrombocytopenia or coagulation disorders.

Discontinue immediately if anaphylaxis or severe allergic reactions occur. Provide appropriate emergency treatment.

It may interfere with certain RSV diagnostic tests (e.g., antigen detection-based assays). RT-PCR is preferred for confirmation.

When using Synagis 50mg Injection, monitor for hypersensitivity reactions, including anaphylaxis, and be prepared to administer epinephrine if necessary. Use with caution in patients with coagulation disorders due to the intramuscular administration. Synagis 50mg Injection may interfere with certain RSV diagnostic tests, potentially causing false negatives; RT-PCR is recommended for confirmation.

Administer Synagis 50mg injection immediately after withdrawing from the vial and discard any unused portion. Keep in mind that Synagis 50mg Injection is intended for the prevention of RSV, not for the treatment of active infections.